1

a) Gross Sales

5021.64

4101.04

Less: Excise Duty

61.04

90.66

Net Sales

4960.60

4010.38

b) Other Operating Income

296.42

220.55

Total Operating Income (a+b)

5257.02

4230.93

2

Expenditure

a) (Increase)/decrease in
     Stock-in-trade and work in progress

(113.55)

(41.37)

b) Consumption of Materials

1892.18

1642.39

c) Purchase of Traded Goods

588.04

470.62

d) Employee Cost

316.99

255.45

e) Depreciation

170.61

130.68

f) Other Expenditure

1540.97

975.48

g) Total

4395.24

3433.25

3

Profit (+)/Loss (-) from Operations before Other Income and Interest (1-2)

861.78

797.68

4

Other Income

69.02

51.99

5

930.80

849.67

6

Interest

33.96

11.70

7

Profit (+)/Loss (-) after Interest (5-6)

896.84

837.97

8

Prior Period Expense

1.32

-

9

Profit (+)/Loss (-) before tax (7-8)

895.52

837.97

10

Tax Expense
a) Current Tax
b) Deferred Tax
c) Fringe Benefit Tax

101.00
15.00
8.50

 
94.00
36.50
6.43

11

Net Profit (+)/Loss (-) after Tax (9-10)

771.02

701.04

12

Paid-up Equity Share Capital
(Face Value Rs.2/- per share)

155.46

155.46

13

Reserves excluding Revaluation
Reserves as per Balance Sheet of previous
Accounting Year

4183.37

3590.74

14

Earning per Share (Rs.)

9.92

9.02

15

Public Shareholding
- Number of Shares
- Percentage of Shareholding

462918088
59.56

465708166
59.91

16

Promoters and Promoter Group Shareholding

a) Pledged/Encumbered
     - Number of Shares
     - Percentage of shares (as a % of the total        shareholding of promoter and promoter group)
     - Percentage of shares (as a % of the total share        capital of the Company)

NIL
NIL

NIL

b) Non Encumbered
     - Number of Shares
     - Percentage of shares (as a % of the total         shareholding of promoter and promoter group)
     - Percentage of shares (as a % of the total share         capital of the Company)

306108047
100.00

39.38

1. The Company is essentially in the pharmaceutical business segment.
2. The Directors at their meeting held today recommended payment of dividend of Rs.2 per equity share (face value Rs.2) for the year 2008-2009 amounting to Rs.155.46 crores.
3. The above results include results of the Company and its wholly owned subsidiary viz., Cipla FZE
4. The Company had challenged the inclusion of the drugs – Salbutamol, Theophylline, Ciprofloxacin, Cloxacillin and Norfloxacin – within the ambit of price control. The petition filed by the Company had been decided in favour of the Company by the Bombay High Court, which held that the said drugs were outside the ambit of price control. However, on an appeal filed by the government, the Supreme Court remanded the matter to the Bombay High Court for further and more detailed examination in the light of the principles laid down by the Supreme Court. Pending this, the Supreme Court also gave liberty to government to recover 50% of the amount that they had claimed was overcharged. The government had sent notices to the Company demanding an aggregate of Rs.180.37 crores in respect of the said drugs, which, according to them, was 50% of the amount allegedly overcharged by the Company till July 2003. The Company had not deposited the amount demanded, as in another petition challenging the price fixation notifications of these drugs, the Karnataka High Court had granted an interim stay against the government. Subsequently, in separate proceedings on the same basis as before the Karnataka High Court, the Allahabad High Court had ruled that the prices fixed by the government in respect of a number of drugs including the above drugs were ultra vires, illegal and void. On an appeal filed by the government against this ruling, the Supreme Court stayed the judgment of the Allahabad High Court but directed that no prosecution should be launched or coercive action taken against the Company for recovery, till the appeal was finally decided. The Company has, subsequently, in April 2007 received demand notices for the entire 100% of the aforesaid amount along with interest, aggregating Rs.748.27 crores - contrary to the orders of the Supreme Court. In addition during the financial year 2007- 2008, the Company has received from the government further demand notices inclusive of interest for Rs.362.12 crores which according to the government was allegedly overcharged by the Company for the period upto March 2007 in respect of the aforesaid drugs. Further the Company has in March 2008 received a demand notice from the government for an amount of Rs.0.32 crores inclusive of interest allegedly overcharged in respect of the drug Doxycycline. In July 2009, the Company has received demand notices for an amount of Rs.64.39 crores including interest in respect of the drug Salbutamol upto June 2009 and an amount of Rs.2.19 (including interest of Rs.0.74 crores upto June 2009) crores in respect of the drug Norfloxacin for the period October 2005 to March 2006. The Company has received legal advice that none of these demand notices of the government is tenable or sustainable.
5. The Audited Standalone financial results is available on the Company's website i.e www.cipla.com
6. The figures of the previous year have been regrouped/recast to render them comparable with the figures of the current year.
7. The above results after being reviewed by the Audit Committee were approved at the meeting of the Board of Directors held on 15 th July, 2009.